Balaxi Pharmaceuticals Limited is listed on the NSE. Auto-imported from the NSE equity master; profile pending.
1,903 historical price candles were omitted because the exchange source has not been verified.
No positive flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Quarterly shareholding records haven't been ingested for this company.
No scheme among the 32 fund houses on record reported a position in Balaxi Pharmaceuticals Limited. Portfolios are published monthly by each AMC; coverage is still partial.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Consolidated figures
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross margin % | 30% | 39.8% | 46.7% | 43.4% | 44.2% |
| EBITDA margin % | 18% | 16.8% | 19.4% | 12.7% | 3.2% |
| EBIT margin % | 17.8% | 16.3% | 18.5% | 12.1% | 2.4% |
| PAT margin % | 17.1% | 13.7% | -1% | 8.6% | 0.5% |
| Working capital | |||||
| Receivable days | — | 58 | 84 | 138 | 184 |
| Inventory days | — | 189 | 233 | 173 | 202 |
| Payable days | — | 66 | 82 | 36 | 51 |
| NWC days | — | 182 | 235 | 275 | 335 |
| Leverage | |||||
| Current ratio | — | 3.64 | 3.88 | 4.45 | 4.04 |
| Debt to EBITDA | — | 0.21 | 0.38 | 1.39 | 6.55 |
| Debt to equity | — | 0.06 | 0.09 | 0.22 | 0.22 |
| Interest coverage | 390.4 | 114.8 | 25 | 10.8 | 2.4 |
| Asset turnover | — | 1.4 | 0.93 | 0.94 | 0.8 |
| Return ratios | |||||
| Return on assets % | — | 19.2% | -0.9% | 8.1% | 0.4% |
| Return on capital employed % | — | 30.8% | 21.5% | 13.7% | 3.5% |
| Return on equity % | — | 25.1% | -1.2% | 10.8% | 0.6% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Annual reports, earnings call transcripts and presentations will appear here once ingested.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Anawil Wire And Engineering LimitedANAWILANAWIL | ₹1,064 Cr | — | — | — | — | — | — | — | — | — |
| Credent Connect N Care LimitedCREDENTCREDENT | ₹696 Cr | — | — | — | — | — | — | — | — | — |
| Metalic Technoforge LimitedMETALICMETALIC | ₹426 Cr | — | — | — | — | — | — | — | — | — |
| Optimystix Entertainment India LimitedOPTIMYSTIXOPTIMYSTIX | ₹307 Cr | — | — | — | — | — | — | — | — | — |
| Pramodini Medicare LimitedPRAMODINIPRAMODINI | ₹254 Cr | ₹271 Cr | ₹62 Cr | — | — | ₹17 Cr | 27.9% | -11.3% | 39.1% | — |
| Annapurna Swadisht LimitedANNAPURNAANNAPURNA | ₹211 Cr | — | ₹520 Cr | ₹72 Cr | 13.9% | ₹32 Cr | 6.2% | — | — | — |
| Fascinate Textiles LimitedFASCINATEFASCINATE | ₹102 Cr | — | — | — | — | — | — | — | — | — |
| Propshop Events And Exhibitions LimitedPROPSHOPPROPSHOP | ₹97 Cr | — | ₹70 Cr | ₹11 Cr | 15.8% | ₹8 Cr | 11.4% | — | — | — |
| Vinod Texworld LimitedVINODVINOD | ₹82 Cr | — | — | — | — | — | — | — | — | — |
| Skytech Infinite Platform LimitedSKYTECHSKYTECH | ₹38 Cr | ₹44 Cr | — | — | — | — | — | — | — | — |
| Dhansa Labs LimitedDHANSADHANSA | — | — | ₹142 Cr | ₹11 Cr | 7.7% | ₹6 Cr | 3.9% | — | — | — |
| Divine Power Energy LimitedDPELDPEL | — | — | ₹626 Cr | ₹51 Cr | 8.1% | ₹27 Cr | 4.3% | — | — | — |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 279 | 336 | 241 | 293 | 270 | |
| COGS | 196 | 202 | 129 | 166 | 151 |
| Gross profit | 84 | 134 | 113 | 127 | 119 |
| 34 | 77 | 66 | 90 | 111 | |
| 50 | 57 | 47 | 37 | 9 | |
| OPM % | 18% | 16.8% | 19.4% | 12.7% | 3.2% |
| Depreciation | 1 | 2 | 2 | 2 | 2 |
| Interest | 0 | 1 | 2 | 3 | 4 |
| 5 | 3 | -41 | -4 | 3 | |
| Profit before tax | 55 | 57 | 2 | 29 | 5 |
| Tax | 7 | 11 | 4 | 4 | 4 |
| Tax % | 12.6% | 19.3% | 217.8% | 12.6% | 73.4% |
| 48 | 46 | -2 | 25 | 1 | |
| PAT margin % | 17.1% | 13.7% | -1% | 8.6% | 0.5% |
| EPS (₹) | 47.7 | 45.8 | -2.3 | 4.5 | 0.3 |
| EPS adjusted (₹) | — | 9 | -0.4 | 4.5 | 0.3 |
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 10 | 11 | 11 | 11 |
| Reserves | 173 | 190 | 221 | 238 |
| Minority interest | — | — | 0 | 0 |
| 12 | 18 | 52 | 56 | |
| 45 | 39 | 27 | 32 | |
| Total equity & liabilities | 240 | 258 | 310 | 337 |
| 41 | 41 | 41 | 82 | |
| CWIP | 3 | 2 | 22 | — |
| Investments | 0 | 0 | 0 | 0 |
| 195 | 215 | 247 | 255 | |
| Total assets | 240 | 258 | 310 | 337 |
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 34 | 6 | 5 | -35 | -5 | |
| -28 | -11 | -1 | -22 | -21 | |
| -0 | 26 | 30 | 34 | 0 | |
| Net cash flow | 6 | 21 | 34 | -23 | -25 |
| Free cash flow | 29 | -5 | 4 | -36 | -19 |
| CFO / Operating profit % | 68% | 10.8% | 10.4% | -94.1% | -52.8% |